Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

519

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg
DRUG: Fluticasone Propionate 250mcg/ salmeterol 50mcg

Sponsor

GlaxoSmithKline